Document ID: chunk:federal_register_of_legislation:F2025C00036:reg:3
Version: federal_register_of_legislation:F2025C00036
Segment Type: reg
Provision Reference: reg 3
Character Range: 214847–216111

3                            (a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and                                                     liquid       oral                     (a) treatment of refractory chronic pain in adult patients; or
                             (b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and                                                                                 (b) treatment of refractory anxiety in adult patients; or
                             (c) the medicine contains no other active ingredients                                                                                                                                                                         (c) treatment of refractory sleep disorders in adult patients; or
                                                                                                                                                                                                                                                           (d) treatment and management of refractory cancer pain in adult patients